

## CURRICULUM VITAE

**Pier Giorgio Mastroberardino, PhD, MBA****Indirizzo**

Erasmus University Medical Center Rotterdam  
Department of Molecular Genetics  
Wytemaweg 80  
3015 CN Rotterdam  
The Netherlands

IFOM, the FIRC Institute of Molecular Oncology  
Via Adamello, 16  
20139 Milan  
Italy

Phone: +31-10-7043206

Email: [p.g.mastroberardino@erasmusmc.nl](mailto:p.g.mastroberardino@erasmusmc.nl)

Email: [piergiorgio.mastroberardino@ifom.eu](mailto:piergiorgio.mastroberardino@ifom.eu)

**RUOLO ATTUALE**

**Group leader**, Department of Molecular Genetics, Erasmus University Medical Centre, Rotterdam, Paesi Bassi

**Principal Investigator**, IFOM Istituto FIRC di Oncologia Molecolare, Milano, Italia

**Ricercatore (RTD-B)**, Dipartimento di Medicina Clinica, Sanità Pubblica, Scienze della Vita e dell'Ambiente (MESVA), Università degli Studi dell'Aquila, L'Aquila, Italia

**PROFILO PERSONALE**

Pier Giorgio Mastroberardino (PGM) ricopre una posizione di Principal Investigator in condivisione tra il Dipartimento di Genetica Molecolare dell'Erasmus Medical Center di Rotterdam e l'IFOM, l'Istituto FIRC di Oncologia Molecolare di Milano. Tale posizione è stata appositamente creata per generare sinergie tra questi due centri di eccellenza. Il laboratorio del Dr. Mastroberardino studia la patogenesi molecolare delle malattie neurodegenerative ed in particolare del morbo di Parkinson. Come indicato dalle pubblicazioni del Dr. Mastroberardino, particolare attenzione è dedicata allo studio dei meccanismi che causano alterazioni alla funzione mitocondriale, al metabolismo del ferro e all'omeostasi ossido-riduttiva in seguito ad esposizione a tossine ambientali. Più recentemente, il laboratorio del Dr. Mastroberardino ha sviluppato interesse nei meccanismi correlati con l'invecchiamento che possono interagire con fattori ambientali e genetici per contribuire all'insorgenza delle malattie neurodegenerative. In quest'ambito, il gruppo del Dr. Mastroberardino studia attivamente i meccanismi di danno e riparazione del DNA in luce del loro ruolo fondamentale nei processi di invecchiamento. Gli studi vengono condotti in molteplici sistemi sperimentali che includono culture cellulari, zebrafish, modelli tossicologici e genetici in roditori, per venire poi estesi agli esseri umani, per esempio in cellule differenziate da staminali riprogrammate.

Il Dr. Mastroberardino ha inoltre conseguito un Global Executive Master in Business Administration (MBA) presso la Rotterdam School of Management (RSM). Al momento, è impegnato ad avviare un nuovo programma di Master tra l'Erasmus Medical Center e la Business School RSM, che ambisce a formare una nuova classe di professionisti con capacità che permettano di operare all'interfaccia tra il mondo della ricerca e quello dell'impresa. In virtù della sua formazione in ambito di business, il Dr. Mastroberardino è anche coinvolto nelle interazioni col settore dell'industria e la valorizzazione di scoperte scientifiche.

Nel loro insieme, questi elementi evidenziano come l'esperienza del Dr. Mastroberardino si integri e completi quella attualmente disponibile nel Dipartimento di Ambiente e Salute dell'Istituto Superiore di Sanità.

**FORMAZIONE**

<b>Global Executive Master in Business Administration OneMBA</b> Rotterdam School of Management, Erasmus University, Paesi Bassi	Giugno 2016
Abilitazione Scientifica Nazionale (ASN) <b>Prima Fascia</b> in <i>Biochimica</i> (05/E1)	2017
Abilitazione Scientifica Nazionale (ASN) <b>Prima Fascia</b> in <i>Anatomia Comparata e Citologia</i> (05/B2)	2018
Idoneità <b>Professore Associato</b> in <i>Anatomia Comparata e Citologia</i> (Università di Roma "Tor Vergata", Roma, Italia, D.R. n. 2033 del 30.09.2014)	Settembre 2014
Abilitazione Scientifica Nazionale (ASN) <b>Seconda Fascia</b> in <i>Biochimica</i> (05/E1), <i>Biologia Molecolare</i> (05/E2), <i>Anatomia Comparata e Citologia</i> (05/B2).	2014
<b>Dottorato in Biologia Cellulare e Molecolare</b> Università di Roma "Tor Vergata", Italia <i>Supervisore</i> : Mauro Piacentini <i>Oggetto ricerca</i> : Ruolo delle transglutaminasi nel cervello <i>Titolo tesi</i> : Transglutaminase 2 regulates the mitochondrial respiratory chain assembly and function under physiological conditions	2000-2004
<b>Laurea, Biologia</b> Università di Roma "Tor Vergata", Italia <i>Supervisore</i> : Mauro Piacentini <i>Oggetto ricerca</i> : Ruolo dell'attività cross-linking delle transglutaminasi nel cervello <i>Thesis</i> : Ruolo della transglutaminase tissutale in un modello murino di corea di Huntington	2000

**ESPERIENZA ACCADEMICA**

<b>Principal Investigator</b> , IFOM, Istituto FIRC di Oncologia Molecolare, Milano, Italia	2020-oggi
<b>Ricercatore (RTD-B)</b> , Dipartimento di Medicina Clinica, Sanità Pubblica, Scienze della Vita e dell'Ambiente (MESVA), Università degli Studi dell'Aquila, L'Aquila, Italia	2018-oggi
<b>Group Leader</b> , Department of Molecular Genetics <i>Direttore</i> : Roland Kanaar, PhD Erasmus University Medical Center, Rotterdam, The Netherlands	2010- oggi
<b>Adjunct Faculty</b> , Department of Neurology, Pittsburgh Institute for Neurodegenerative Diseases <i>Direttore</i> : J. Timothy Greenamyre, MD, PhD University of Pittsburgh, Pittsburgh, PA, USA	2010- oggi
<b>Visiting Professor</b> , Dipartimento di Medicina Clinica, Sanità Pubblica, Scienze della Vita e dell'Ambiente (MESVA), Università degli Studi dell'Aquila, L'Aquila, Italia <i>Direttore</i> : Grazia Cifone, MD	2017

- Post-doctoral associate**, Department of Neurology 2005-2010  
 Pittsburgh Institute for Neurodegenerative Diseases  
 University of Pittsburgh, Pittsburgh, PA, USA  
*Supervisore*: J. Timothy Greenamyre, MD, PhD  
*Oggetto ricerca*: Pathological molecular mechanisms in Parkinson's, and Huntington's disease
- Post-doctoral fellow**, Department of Neurology 2003-2005  
 Center for Neurodegenerative Diseases  
 Emory University, Atlanta, GA, USA  
*Supervisore*: J. Timothy Greenamyre, MD, PhD  
*Oggetto ricerca*: Pathological molecular mechanisms in Parkinson's and Huntington's disease

### Altre esperienze professionali

- Consulente Research Management**, IRCCS Fondazione Mondino, Pavia, 2018  
 Italia
- Training in spettrometria di massa applicate alle scienze biologiche 2002  
 Universiteit Gent, Belgium  
*Supervisore*: Joseph van Beeumen, PhD
- Internato in biologia cellulare e dello sviluppo 1998-2000  
 Università di Roma "Tor Vergata", Italia  
*Supervisore*: Mauro Piacentini, PhD

### GRANT SUPPORT

#### In fase di valutazione

- **European Joint Programme on Rare Diseases (EJP RD)** – “Transcription stress Counteracted by Nutritional interventions of Exceptional importance for rare DNA Repair disorders” (**work-package leader**)  
 SELEZIONATO PER IL FINANZIAMENTO dall’Agenzia europea nella Final Funding Decision; in attesa della comunicazione al Ministero dell’istruzione, della Ricerca e dell’Università  
 EUR 150,000 assegnati al laboratorio Mastroberardino

#### Attivi

- **Eurostars-Eureka Horizon 2020** - E! 114370 PD-IRONSYN – “Novel Parkinson's Disease therapy targeting iron-related cell death and alpha synuclein aggregation” (**work-package leader**)  
**EUR 307,150 (subsidy) – EUR 307,150 co-finance** 2020-2023
- **The Michael J. Fox Foundation for Parkinson's Research** – “Orthogonal validation of mitochondrial anomalies in patients' derived multiple cellular systems” – (PI)  
**USD 149,975** 2020-2021
- **Italian Medicines Agency (AIFA)** - “*Biological markers of frailty in the physiological and pathological aging brain: correlations with pharmacological frailty*” (**work-package leader**)  
**EUR 650.200 totale, EUR 125.000** assegnati al laboratorio Mastroberardino 2018-2021

**Completati**

- **The Michael J. Fox Foundation for Parkinson's Research** – “*Transferrin Receptor 2 as a target to halt nigral neurons iron overload in Parkinson's disease*” (PI);  
**US\$ 250.000** 2015-2016
- **Stichting Alkemade-Keuls** – “*Molecular markers of skin fibroblasts of Parkinson's disease*” (co-PI)  
**EUR 80.000** 2015-2016
- **Ri.MED Foundation** – “*Zebrafish as a redox-sensitive vertebrate model to study redox homeostasis and to identify new potential treatments for PD*” (Supervisor);  
**EUR 195.000** 2014-2016
- Erasmus MC Pilot grant MRACE “Cancer Cachexia in Surgical Oncology – Mechanisms and Interventions” (co-project leader);  
**EUR 56.100** 2014-2015
- “*Dorpmans-Wigmans Stichting*” Foundation for Parkinson's and Alzheimer research Subsidy to purchase a Seahorse Extracellular Flux Analyzer (PI);  
**EUR 53'105** 2011
- **Dutch Center for Cancer Genomics**, Junior Group Leader subsidy (NGI/NWO 05040202) (PI);  
**EUR 650'000** 2010-2014
- FP7-Fission-2011, Proposal N° 295552, “CEREBRAD—Cognitive and Cerebrovascular Effects Induced by Low Dose Ionizing Radiation” (**work-package leader**);  
**EUR 374'000** 2011-2015
- Marie Curie Reintegration Grant (FP7) - Proposal N° 247918 – “The synergistic effect of DNA damage and oxidative stress in the aging brain” (PI)  
**EUR 25'000/year – 4 years - EUR 100'000 total** 2009-2013
- NIH Pathway to Independence Award K99/R00, ES016352, “Oxidative modification of brain proteins in pesticide intoxication” (PI).
  - R00 phase: 2009-2012, **\$249'000/year – 3 years - \$747'000 total**; upon acceptance of a tenure-track faculty position in the United States; funds for the R00 phase were returned to the Agency upon relocation to Europe.
- **Ri.MED Foundation** – “*Zebrafish as a redox sensitive vertebrate model to study oxidative damage in brain*” (Supervisor);  
**EUR 120'000** 2011-2012
- K99 supplement under the American Recovery and Reinvestment Act of 2009 (PI); **\$89'758** 2009-2010
- NIH Pathway to Independence Award K99/R00, ES016352, “Oxidative modification of brain proteins in pesticide intoxication” (PI).
  - K99 phase: **\$90'000/year – 2 years - \$180'000 total** 2007-2009
- Michael J. Fox Foundation Post Doctoral Fellowship 2004-2005
- European Science Foundation Scholarship 2002

- European Science Foundation short-term fellowship 2002
- University of Rome "Tor Vergata", grant for young researchers 2001

### Altri riconoscimenti

- **Certificate of Reviewing Excellence** from Elsevier and the Editors of *Neurobiology of Disease*. 2014
- International Bioiron Society Travel Bursary 2009

### BREVETTI

- "Method of labeling biological samples" – Patent Number(s): WO2009129472-A2 ; WO2009129472-A3 ; US2011039277-A1.

### INTERESSI DI RICERCA

- **Meccanismi cellulari attivati dall'esposizione a tossine ambientali e a pesticidi, e loro ruolo nell'insorgenza delle malattie neurodegenerative legate all'invecchiamento**
  - Modelli genetici e tossicologici di malattie neurodegenerative in culture cellulari, culture organotipiche tissutali, zebrafish e roditori
  - Circuiti redox e loro alterazioni fisiologiche e patologiche
  - Ruolo del danno al DNA e dell'instabilità genomica nelle malattie neurodegenerative
  - Metodi proteomici applicati allo studio di modificazioni ossidative
  - Omeostasi del ferro
  - Sviluppo di biomarkers
  - Sviluppo di terapie sperimentali
- **Metabolismo, funzione mitocondriale ed enzimi della catena di trasporto elettronica mitocondriale**
  - Meccanismi di adattamento metabolico a seguito di danno al DNA e attivazione della riparazione
  - Meccanismi di adattamento metabolico a seguito di aggregazione di specie proteotossiche nelle malattie neurodegenerative
  - Meccanismi di adattamento metabolico a seguito di esposizione ambientale a neurotossine legate all'insorgenza di malattie neurodegenerative
- **Imaging**
  - Sviluppo di tecniche di imaging in fluorescenza per rilevare danno ossidativo a livello istologico e citologico
  - Uso della fluorescent resonance energy transfer (FRET) per lo studio delle modificazioni ossidative in proteine interazione proteina-proteina
  - Sviluppo di sensori redox per studi *in vivo*

**RUOLI EDITORIALI****Associate Editor**

<i>Frontiers in Cellular Neuroscience</i>	2015-oggi
<i>Frontiers in Molecular Neuroscience</i>	2020

**Editorial Board**

<i>Cell Death and Disease</i> (Nature Publishing Group)	2018-oggi
<i>Neurobiology of Disease</i> (Elsevier)	2010-2020

**Guest Editor**

*Neurobiology of Disease* - Guest Editor per lo special issue "**Metals, the Brain, and Neurodegeneration**" (2015)

*Frontiers in Cellular Neuroscience* – Guest Editor per lo Special Issue "**Neuronal self-defense: compensatory mechanisms in neurodegenerative disorders**" (2014)

*Antioxidant & Redox Signaling* – Guest Editor per lo special issue "**Peripheral Neuropathies**" (published in volume 4, issue 2, August 2014)

*International Journal of Cell Biology* - Guest Editor per lo special issue "**Redox Status and Bioenergetics Liaison in Cancer and Neurodegeneration**" (2012)

**Ad Hoc Reviewer (selected)**

Cell Death and Differentiation	Nature Medicine
The Journal of Neurochemistry	Cell Metabolism
Neurobiology of Disease	The Journal of Cell Biology
Neurochemical Research	Brain
The Journal of Neuroscience	Free Radical Biology and Medicine
Neurobiology of Aging	Antioxidant & Redox Signaling
Nature Neuroscience	EMBO Molecular Medicine
Nature	Experimental Neurology
Biochimie	Neuropharmacology
Movement Disorders	

**ALTRI RUOLI**

<b>Ad hoc grant reviewer</b> Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR), FISR 2020	Dic 2020
<b>Membro della review study section</b> per la valutazione dei progetti Ricerca Finalizzata (senior) del Ministero della Salute	Sett 2020
<b>Ad hoc grant reviewer</b> European Science Foundation – University of Antwerp Centres of Excellence scheme	2019
<b>Ad hoc grant reviewer</b> European Science Foundation – Research Foundation Flanders' (FWO) postdoctoral fellowships	2019

<b>Membro della review study section</b> per la valutazione dei progetti Ricerca Finalizzata (senior) del Ministero della Salute	Nov 2017
<b>Membro esterno</b> della commissione per il concorso di Ricercatore in Patologia Generale (S.S.D. MED/04), Dipartimento di Medicina Clinica, Sanità Pubblica, Scienze della Vita e dell'Ambiente (MESVA), Università degli Studi dell'Aquila, L'Aquila, Italia	Ago 2017
<b>Scientific Expert Reviewer</b> grant Agenzia Italiana del Farmaco (AIFA)	Mag 2017
<b>Ad hoc grant reviewer</b> European Commission Research Executive Agency (REA) – Marie Skłodowska-Curie Action – Individual Fellowship	2018-2020
<b>Ad hoc grant reviewer</b> European Commission Research Executive Agency (REA) – Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)	2017-2019
<b>Ad hoc grant reviewer</b> Association of British Neurologists	Gen 2016
<b>Ad hoc grant reviewer e membro del Review Committee</b> Michael J. Fox Foundation <i>Target Advancement Fall 2015</i> program	Sett 2015
<b>Presidente della study section</b> per la valutazione dei progetti Ricerca Finalizzata (senior) del Ministero della Salute	Giu 2015
Ha contribuito a formulare le linee guida per la valutazione dei progetti del Ministero della Salute nell'ambito " <i>Ricerca Finalizzata</i> " e " <i>Giovani Ricercatori</i> "	Mag 2013
<b>Rappresentante</b> per i Paesi Bassi nel <b>Management Committee</b> dell-European intergovernmental framework COST CM1001 " <i>Chemistry of non-enzymatic protein modification - modulation of protein structure and function</i> "	2012 - 2015
<b>Ad hoc grant reviewer</b> per la Michael J. Fox Foundation for Parkinson's Research	Ago 2011
<b>Ad hoc grant reviewer</b> Telethon Italia	2011
<b>Ad hoc grant reviewer</b> for the Italian Ministry of Health projects " <i>Ricerca Finalizzata</i> " and " <i>Giovani Ricercatori</i> "	2009 - 2012
<b>Member of the review study section</b> per la valutazione dei progetti Ricerca Finalizzata " <i>Giovani Ricercatori</i> " del Ministero della Salute	2009 e 2011
Ha contribuito al workshop <i>WhyWeAge</i> che ha definito le priorità della ricerca nel campo dell'invecchiamento in Europa. I risultati sono apparsi nel documento " <i>A European road map for molecular biogerontology</i> ", che ha costituito un riferimento per la Commissione Europea per pianificare le strategie di finanziamento in Horizon 2020	Mar-Mag 2010
<b>Abstract Reviewer</b> 17th meeting annuale della <i>Society for Free Radical Biology and Medicine</i> (SFRBM)	Oct 2010

## ATTIVITÀ MANAGERIALI ED IMPRENDITORIALI

Subito dopo aver conseguito il Master in Business Administration, il Dr. Mastroberardino ha iniziato attività manageriali e imprenditoriali.

- PGM ha avviato una start-up (Askesis BV) che, sulla base dei risultati ottenuti nei suoi laboratori, si prefigge di sviluppare supplementi nutritivi che mitigano

gli effetti dell'invecchiamento e contrastino le malattie neurodegenerative

- PGM è in procinto di avviare un programma di Master tra l'Erasmus Medical Center e la Rotterdam School of Management su innovazione e imprenditorialità in medicina. Il programma formerà professionisti capaci di operare all'interfaccia tra ricerca e business, e coinvolgerà diverse imprese. Data di inizio: Settembre 2022.
- PGM ha preparato - in collaborazione con il Case Development Centre della Rotterdam School of Management – la sezione *Strategy and Entrepreneurship* da sottomettere al comitato internazionale per la valutazione dell'operato dell'Erasmus Research Institute of Management (Erasmus University).

## INSEGNAMENTO

### **Supervisore di ricerca**

2002-oggi

- *Università di Roma "Tor Vergata"*: un laureando (Valentina Spina) ed uno studente di dottorato (Irene Viti)
- *Emory University*: uno studente di dottorato (Adam Orr)
- *University of Pittsburgh*: uno studente di dottorato (Maxx Horowitz), due tecnici (Hye Mee Na, Xiaoping Hu), and due junior post-doctoral fellows (Roberto Di Maio, Chiara Milanese)
- *Erasmus Medical Centre*: tre visiting PhD students (Sara Sepe and Luana Barone, dall'Università Roma Tre, Italia, Giulia Ambrosi, Università di Pavia, Italia), due tecnici (Humaira Yousaf, Sylvia Gabriels), cinque postdoctoral fellows (Sara Sepe, Chiara Milanese, Cintia Bombardieri, Marshall Huston, Manuela D'Eletto), sei studenti undergraduate (Casper Ouwkerk, Marco Nigro, Robin de Jong, Leander Vermeer, Kawita Dihal, Ronnie de Bor).

### **Insegnamento**

#### *Visiting Professor*

2018, 2020

Università of Pavia, Scuola Universitaria Superiore Pavia (IUSS)  
Master in Psychology, Neuroscience, and Human Sciences  
Ha insegnato (24 ore totali, in inglese) a studenti di Master e di Dottorato circa:

- *Presentation skills and scientific communication*
- *Grant writing*
- *Navigating the scientific peer review process*

#### *Ricercatore RTD-B*

2018-oggi

Dipartimento di Medicina Clinica, Sanità Pubblica, Scienze della Vita e dell'Ambiente (MESVA), Università degli Studi dell'Aquila, L'Aquila, Italia

- *Istologia (40 ore/anno, approx. 50 studenti laurea triennale)*
- *Biologia Cellulare (30 ore/anno, approx. 20 studenti laurea triennale)*
- *Biotechnologie del Sistema nervosa umano (45 ore/anno hours, approx. 20 studenti laurea magistrale)*

- *Soft Skills in Biomedical Science (20 ore/anno, approx. 50 studenti laurea triennale e magistrale)*

**Visiting Professor**

2017

Dipartimento di Medicina Clinica, Sanità Pubblica, Scienze della Vita e dell'Ambiente (MESVA), Università degli Studi dell'Aquila, L'Aquila, Italia

Ha insegnato (in inglese) a studenti di Master e di Dottorato circa:

- *Neurobiology of disease*
- *Bioenergetics and redox biochemistry*
- *DNA damage and repair*
- *In vitro models of neurodegenerative diseases*

Ha tenuto il corso "**Survival skills**" circa:

- *Presentation skills and scientific communication*
- *Grant writing*
- *Navigating the scientific peer review process*

Assistente nel corso di Genetica

Erasmus University Medical Center

Ha insegnato due volte a settimana per 4 settimane a circa 50 studenti di Medicina

Ha insegnato per 7 semestri

2011-2019

Invited Panelist, "*K99/R00 Career Development Award Workshop*"

University of Pittsburgh

Office of Academic Career Development

2007-2009

Assistente nel corso di Istologia

Università di Roma "Tor Vergata"

Ha sostenuto le esercitazioni di istologia due volte a settimana a circa 30 studenti del corso di laurea in Biologia

Ha insegnato per 3 semestri

2001-2003

**Partecipazione in comitati di tesi di dottorato**

**Presidente** della commissione per il PhD in "*Biotechnologie Cellulari e Molecolari – XXXII ciclo*" Università di Teramo, Teramo, Italia

18 settembre 2020

**Presidente** della commissione per il PhD in "*Biotechnologie Cellulari e Molecolari – XXIX ciclo*" Università di Teramo, Teramo, Italia

12 Giugno 2017

**Al momento, tutore** della studentessa di dottorato Martina Sette (Dottorato in *Biotechnologie Cellulari e Molecolari*, Università di Teramo, Università degli studi dell'Aquila) – **Argomento di ricerca:** metabolismo del ferro nel morbo di Parkinson.

**Co-tutor** nelle seguenti tesi di dottorato:

Candidata/o	Istituzione	Titolo della tesi	Data discussione
Luana Barone	Università "Roma Tre", Roma, Italia	Alterations in peroxisomal function induced by genomic instability and their relevance for aging	17 Feb 2016

Sara Sepe	Universita' "Roma Tre", Roma, Italia	Role of AMBRA1 in nervous tissue homeostasis and in neurodegeneration	19 Dic 2011
-----------	--------------------------------------	---	-------------

### Referee e membro della commissione nelle seguenti tesi e sedute di dottorato:

Candidata/o	Istituzione	Titolo della tesi	Data discussione
Kornvalee Meesilpavikkai	Erasmus University Medical Center	The State of STATs in Primary Immunodeficiencies: Molecular Diversity and Implications for Therapy	9 Ott 2019
Gloria Panella	University of L'Aquila, L'Aquila, Italy	Design and characterization of biocompatible scaffolds for tissue regeneration	Mar 2018
Monique Corbin	Vrije Univesiteit Medical Center Amsterdam (VUmc)	Mechanisms in the cellular defense against oxidative stress	9 Nov 2017
Alessia Buso	University of Udine, Udine, Italy	Mitochondrial oxidative phosphorylation plasticity/adaptation triggered by disturbances and stresses and targeted by therapies	30 Mag 2017
Nada Samari	Vrije Univesiteit Brussel and Studiumcentrum voor Kernenergie, Belgium	Molecular and morphological changes induced by ionizing radiation on maturing neurons	21 Feb 2013

### CORSI (selezione)

Biological Basis of Neuropsychiatric Disorders University of Pittsburgh	2008
Course in Scientific Management and Leadership University of Pittsburgh	2008
"IV course on proteomics" University of Siena, Italy and Amersham Pharmacia	2001

### MEMBRO DI SOCIETA' PROFESSIONALI

- Society for Neuroscience (2003-oggi)
- Nitric Oxide Society (2014)
- The New York Academy of Science (2007)
- Society of Toxicology (2008)
- Society for Free Radical Biology and Medicine (2004)

### SEMINARI SU INVITO (selezione)

- Giu 2019 – Gordon Research Conference on Parkinson's disease, Grand Summit Hotel at Sunday River, Newry, ME, **Invited Speaker**
- Apr 2018 – Norwegian "NeuroMito" symposium on "Interconnected networks between DNA damage and mitochondrial dysfunction in neurodegeneration" – Bergen, Norvegia – **Keynote Lecture**
- Apr 2018 – Dutch Society for Clinical Pharmacology and Biopharmacy Scientific Spring Meeting – Utrecht, Paesi Bassi, **Invited speaker**

- Sett 2017- 6<sup>th</sup> EU-US Conference on Repair of endogenous DNA damage , Udine, Italia, **invited speaker**
- Ago 2016 – Benzon Symposium no.62 – Genome Instability and Neurodegeneration, Copenhagen, Danimarca, **invited speaker**
- Mag 2016 - Istituto Superiore di Sanità, Roma, Italia
- Dic 2015 – University of Cologne, Colonia, Germania
- Giu 2015 – Seahorse Biosciences User Group Meeting 2015, Amsterdam, Paesi Bassi, June 2-4 2015, **invited speaker**
- Sept 2014 - Society for Free Radical Research-Europe, 2014 Meeting, Parigi, Francia, **invited speaker**
- June 2014 – Nitric Oxide - Nitrite/Nitrate Conference, Cleveland, OH, USA, **invited speaker**
- June 2014 – University of Pittsburgh, Pittsburgh, PA, USA
- May 2014 – Università degli Studi di Chieti “G.D’Annunzio”, Italia
- May 2014 - 4<sup>th</sup> Dutch Huntington’s Disease Research Network (DHDRN) Symposium, Amsterdam, Paesi Bassi, **Keynote Lecture**
- Jan 2014 – Università di Roma, Tor Vergata, Dipartimento di Biologia, Roma, Italia
- May 2013 – Helmholtz Zentrum München, Institute for Radiation Biology, in the “*TIETO: Non-cancer effects of low dose ionizing radiation Course*”, Monaco di Baviera, Germania, **invited speaker**
- Apr 2013 – Gordon Research Conference “Oxidative Stress And Disease”, **invited speaker**
- Sept 2012- IRRCS “C.Mondino”, Pavia, Italia, in “XXIII OTTORINO ROSSI AWARD”, **invited speaker**
- Jun 2012 - A. I. Virtanen Institute for Molecular Sciences- University of Eastern Finland, in “*Mitochondria and oxidative stress in the nervous system Course*”, **invited speaker**
- Dec 2012 – Università di Roma, Tor Vergata, Dipartimento di Biologia, Roma, Italia
- Jan 2011 - Institute for Ageing and Health, Newcastle University, UK, in “*Academic Ageing Seminar Programme*”
- Nov 2010 – Institut Curie à Orsay, Centre Universitaire Paris-Sud 11, Francia
- May 2010 – A. I. Virtanen Institute, University of Eastern Finland Kuopio, Finlandia
- March 2009 – Dept. of Physiology, University of Texas San Antonio Health Science Center, San Antonio, TX, USA
- October 2008 – Hillman Cancer Center, University of Pittsburgh, PA, USA
- October 2008 – Erasmus Medical Center, Rotterdam, Paesi Bassi
- October 2007 – Buck Institute for Age Research, Novato, CA, USA
- March 2007 – Istituto “L. Spallanzani”, Roma, Italia
- February 2007 – Università di Roma “Tor Vergata”, Dipartimento di Biologia, Italia

### Abstract (selezione)

- Sepe S, Milanese C, Gabriels S, Derks K, Payan-Gomez C, van IJcken W, Battaglia G, van Cappellen G, Niggs A, Blandini F, Hoeijmakers JH, and **Mastroberardino PG** Jul 2015  
 Inefficient DNA repair is an aging-related modifier of Parkinson disease  
 Gordon Research Conference “Parkinson disease”, Colby-Sawyer College, NH, USA
- Sepe S, Milanese C, Gabriels S, Derks K, Payan-Gomez C, van IJcken W, Battaglia G, van Cappellen G, Niggs A, Blandini F, Hoeijmakers JH, and **Mastroberardino PG** Dec 2013  
*Aging-related mild genomic instability perturbs the dopaminergic system and elicits salient pathogenic features of Parkinson’s disease pathology*  
 XX World Congress on Parkinson’s Disease and Related Disorders, Geneva, Switzerland, 8-11 December 2013 – **selected for oral presentation**
- Sepe S, Milanese C, Gabriels S, Derks K, Payan-Gomez C, van IJcken W, Battaglia G, van Cappellen G, Niggs A, Blandini F, Hoeijmakers JH, and **Mastroberardino PG** Sept 2013  
*Aging-related mild genomic instability perturbs the dopaminergic system and elicits salient pathogenic features of Parkinson’s disease*  
 The 5<sup>th</sup> EMBO meeting, Amsterdam, the Netherlands

- Sara Sepe received an EMBO travel fellowship and the abstract has been selected for an oral presentation

- Milanese C, Sepe S, Shiva S, Gladwin MT, and **Mastroberardino PG** Sept 2013  
*Nitrite administration ameliorates mitochondrial bioenergetics and is neuroprotective in cellular and vertebrate models of Parkinson's disease*  
 The 5<sup>th</sup> EMBO meeting, Amsterdam, the Netherlands
- Chiara Milanese received an EMBO travel fellowship and the abstract has been selected for a flash talk
- Bombardieri C, Sepe S, Payan Gomez C, Wamelink M, de Wit A, Leen R, van Kuilenburg ABP, Hoeijmakers JH, and **Mastroberardino PG** Aug 2013  
*DNA damage-induced transcription arrest elicits allosteric redesign of metabolism and activation of longevity pathways*  
 Gordon Research Conference "Biology of Aging", Il Ciocco, Italy
- Bombardieri C, Sepe S, Hoeijmakers J, and **Mastroberardino PG** Aug 2012  
*The nucleotide pool integrates genomic stability, metabolism, and redox homeostasis*  
 Gordon Research Conference "Thiol-based redox regulation & signaling", Bates College, ME, USA
- Horowitz M, Milanese C, Di Maio R, Hu X, Montero LM, Tapias V, Burton EA, Greenamyre, JT, and **Mastroberardino PG** Sept 2010  
*Single-cell Redox Imaging Demonstrates a Peculiar Response of Dopaminergic Neurons to Oxidative Insults*  
 2nd World Parkinson Congress, Glasgow, Scotland
- Horowitz M, Milanese C, Di Maio R, Hu X, Montero LM, Tapias V, Burton EA, Greenamyre, JT, and **Mastroberardino PG** Aug 2010  
*Single-cell redox imaging to determine variations in oxidative tolerance of dopaminergic neurons during aging*  
 Gordon Research Conference "Biology of Aging" Les Diablerets, Switzerland
- Horowitz M, Milanese C, Di Maio R, Hu X, Montero LM, Tapias V, Burton EA, Greenamyre, JT, and **Mastroberardino PG** May 2010  
*Single-cell redox imaging demonstrates a distinctive response of dopaminergic neurons to oxidative insults*  
 Gordon Research Conference "Thiol-based redox regulation & signaling", Il Ciocco, Italy
- Mastroberardino PG**, Horowitz MP, Betarbet R, Gutekunst CA, Gearing M, Trojanowski JQ, Anderson M, Chu CT, Peng J and Greenamyre JT Jun 2009  
*A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease*  
 International Biolron Society 2009 Annual Meeting
- Mastroberardino PG**, Hoffman EH, Horowitz MP, Na HM, Chu CT, Gearing M, Greenamyre JT Nov 2008  
*A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease*  
 38<sup>th</sup> annual meeting of the Society for Neuroscience, Washington, DC.
- Mastroberardino PG**, Betarbet R, Uechi G, Chu CT, Gearing M, Greenamyre JT May 2008  
*A novel transferrin/TfR2-mediated mitochondrial iron transport system is sensitive to thiol oxidation and is disrupted in Parkinson's disease*  
 Gordon Research Conference "Thiol-based redox regulation & signaling", Il Ciocco, Italy
- Mastroberardino PG**, McComrack AL, Di Monte DA, Miller GW, Greenamyre JT Mar 2008  
*Characterization of the differences in the oxidative events in two different pesticide models of Parkinson's disease*  
 47<sup>th</sup> annual meeting of the Society of Toxicology meeting, Seattle, WA.
- Mastroberardino PG**, Hoffman EH, Horowitz MP, Na HM, Chu CT, Gearing M, Greenamyre JT Nov 2007  
*A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease*  
 37<sup>th</sup> annual meeting of the Society for Neuroscience, Washington, DC.

- Mastroberardino PG**, Hoffman EH, Na HM, Gearing M, Chu CT, Greenamyre JT Sep 2007  
*Transferrin(Tf) Transferrin Receptor 2 (TfR2) mediate a redox sensitive pathway for iron delivery to mitochondria*  
 Academy conference on Mitochondria and Oxidative Stress in Neurodegenerative Disorders; The New York Academy of Science, New York
- Mastroberardino PG**, Orr AL, Li XJ, Panov A, Shalbuyeva N, Greenamyre JT Aug 2006  
*Mitochondrial aspartate aminotransferase interacts with huntingtin in HD*  
 Hereditary Disease Foundation (CAG)<sub>n</sub> meeting, Boston, MA.

## Pubblicazioni

### Capitoli di libro sottoposti a peer-review

Chiara Milanese and **Mastroberardino PG**  
*Genes, Aging, and Parkinson's Disease in Oxidative Stress and Redox Signalling in Parkinson's Disease*, published by *The Royal Society of Chemistry*

### Articoli su rivista internazionale sottoposti a peer review

P.G. Mastroberardino ha pubblicato 54 articoli in riviste internazionali sottoposte a peer-review. I suoi lavori hanno raccolto piu' di 2900 citazioni con un h-index di 28 (Scopus).

- 54 Milanese C, Gabriels S, Barnhoorn S, Cerri S, Ulusoy A, Gornati SV, Wallace DF<sup>5</sup>, Blandini F, Di Monte DA, Subramaniam VN, and **Mastroberardino PG**  
*Gender biased neuroprotective effect of Transferrin Receptor 2 deletion in multiple models of Parkinson's disease*  
**Cell Death Diff** in press
- 53 Milanese C and **Mastroberardino PG**  
*A perspective on DNA damage-induced potentiation of the pentose phosphate shunt and reductive stress in chemoresistance*  
**Mol Cell Oncol**. 2020 Mar 22;7(3):1733383. doi: 10.1080/23723556.2020.1733383.
- 52 Milanese C, Bombardieri CR, Sepe S, Barnhoorn S, Payán-Gómez C, Caruso D, Audano M, Pedretti S, Vermeij WP, Brandt RMC, Gyenis A, Wamelink MM, de Wit AS, Janssens RC, Leen R, van Kuilenburg ABP, Mitro N, Hoeijmakers JHJ, **Mastroberardino PG**.  
*DNA damage and transcription stress cause ATP-mediated redesign of metabolism and potentiation of anti-oxidant buffering*  
**Nat Commun**. 2019 Oct 25;10(1):4887. doi: 10.1038/s41467-019-12640-5.
- 51 Vandervore LV, Schot R, Milanese C, Smits DJ, Kasteleijn E, Fry AE, Pilz DT, Brock S, Börklü-Yücel E, Post M, Bahi-Buisson N, Sánchez-Soler MJ, van Slegtenhorst M, Keren B, Afenjar A, Coury SA, Tan WH, Oegema R, de Vries LS, Fawcett KA, Nikkels PGJ, Bertoli-Avella A, Al Hashem A, Alwabel AA, Tiili-Graies K, Efthymiou S, Zafar F, Rana N, Bibi F, Houlden H, Maroofian R, Person RE, Crunk A, Savatt JM, Turner L, Doosti M, Karimiani EG, Saadi NW, Akhondian J, Lequin MH, Kayserili H, van der Spek PJ, Jansen AC, Kros JM, Verdijk RM, Milošević NJ, Fornerod M, **Mastroberardino PG**, Mancini GMS.  
*TMX2 Is a Crucial Regulator of Cellular Redox State, and Its Dysfunction Causes Severe Brain Developmental Abnormalities*  
**Am J Hum Genet**. 2019 Dec 5;105(6):1126-1147. doi: 10.1016/j.ajhg.2019.10.009.
- 50 Milanese C, Payán-Gómez C., and **Mastroberardino PG**  
*Cysteine oxidation and redox signaling in dopaminergic neurons physiology and in Parkinson's disease*  
**Current Opinion in Physiology**, 2019 9, pp. 73-78 *in press*

- 49 Milanese C, Payan-Gomez C, Galvani M, Molano González N, Tresini M, Nait Abdellah S, van Roon-Mom WMC, Figini S, Marinus J, van Hilten J, and **Mastroberardino PG**  
*Peripheral mitochondrial function correlates with clinical severity in idiopathic Parkinson's disease*  
**Mov Disord.** 2019 May 28. doi: 10.1002/mds.27723. **Certified by the Journal as one of its top-downloaded paper in 2018-2019.**
- 48 Cerri S, Milanese C, and **Mastroberardino PG**.  
*Endocytic iron trafficking and mitochondria in Parkinson's disease.*  
**Int J Biochem Cell Biol.** 2019 May;110:70-74. doi: 10.1016/j.biocel.2019.02.009.
- 47 van Beek AA, Van den Bossche J, **Mastroberardino PG**, de Winther MPJ, Leenen PJM.  
*Metabolic Alterations in Aging Macrophages: Ingredients for Inflammaging?*  
**Trends Immunol.** 2019 Jan 6. pii: S1471-4906(18)30235-7. doi: 10.1016/j.it.2018.12.007.
- 46 Gardiner SL, Milanese C, Boogaard MW, Buijsen RAM, Hogenboom M, Roos RAC,  
**Mastroberardino PG**, van Roon-Mom WMC, Aziz NA.  
*Bioenergetics in fibroblasts of patients with Huntington disease are associated with age at onset.*  
**Neurol Genet.** 2018 Oct 4;4(5):e275. doi: 10.1212/NXG.0000000000000275.
- 45 Milanese C, Cerri S, Ulusoy A, Gornati SV, Plat A, Gabriels S, Blandini F, Di Monte DA,  
Hoeijmakers JH, and **Mastroberardino PG**.  
*Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson's disease*  
**Cell Death Dis.** 2018 Jul 26;9(8):818. doi: 10.1038/s41419-018-0848-7
- 44 van der Pluijm I, Burger J, van Heijningen PM, Ijpma A, van Vliet N, Milanese C,  
Schoonderwoerd K, Sluiter W, Ringuette LJ, Dekkers DHW, Que I, Kaijzel EL, Te Riet L,  
MacFarlane E, Das D, van der Linden R, Vermeij M, Demmers JA, **Mastroberardino PG**, Davis  
EC, Yanagisawa H, Dietz H, Kanaar R, Essers J.  
*Decreased mitochondrial respiration in aneurysmal aortas of Fibulin-4 mutant mice is linked to  
PGC1A regulation*  
**Cardiovasc Res.** 2018 Jun 21. doi: 10.1093/cvr/cvy150.
- 43 Milanese C, Tapias V, Gabriels S, Cerri S, Levandis G, Blandini F, Tresini M, Shiva S,  
Greenamyre JT, Gladwin MT, and **Mastroberardino PG**  
*S-nitrosation by inorganic nitrite ameliorates complex I dysfunction and is neuroprotective in  
Parkinson's disease*  
**Antioxid Redox Signal.** 2017 Sep 21. doi: 10.1089/ars.2017.6992.
- 42 Zambetti NA, Ping Z, Chen S, Kenswil KJG, Mylona MA, Sanders MA, Hoogenboezem RM,  
Bindels EMJ, Adisty MN, Van Strien PMH, van der Leije CS, Westers TM, Cremers EMP,  
Milanese C, **Mastroberardino PG**, van Leeuwen JPTM, van der Eerden BCJ, Touw IP, Kuijpers  
TW, Kanaar R, van de Loosdrecht AA, Vogl T and Raaijmakers MHGP  
*Oncogenic niche signaling in human leukemia predisposition syndromes*  
**Cell Stem Cell,** 2016 Nov 3;19(5):613-627. doi: 10.1016/j.stem.2016.08.021
- 41 Sepe S, Milanese C, Gabriels S, Derks K, Payán-Gómez C, van IJcken W, Rijksen YMA, Niggs A,  
Moreno S, Cerri S, Blandini F, Hoeijmakers JH, and **Mastroberardino PG**  
*Inefficient DNA repair is an aging-related modifier deranging the dopaminergic system and  
predisposing to Parkinson's disease*  
**Cell Reports** 2016 May 31;15(9):1866-75. doi: 10.1016/j.celrep.2016.04.071.
- 40 Karapiperis C, Kempf SJ, Quintens R, Azimzadeh O, Vidal VL, Pazzaglia S, Bazyka D,  
**Mastroberardino PG**, Scouras ZG, Tapio S, Benotmane MA, Ouzounis CA.  
Brain Radiation Information Data Exchange (BRIDE): integration of experimental data from low-  
dose ionising radiation research for pathway discovery.  
**BMC Bioinformatics.** 2016 May 11;17(1):212. doi: 10.1186/s12859-016-1068-8.
- 39 Parlato R, **Mastroberardino PG**.  
*Editorial: Neuronal Self-Defense: Compensatory Mechanisms in Neurodegenerative Disorders.*  
**Front Cell Neurosci.** 2016 Jan 5;9:499.

- 38 Kempf SJ, Sepe S, von Toerne C, Janik D, Neff F, Hauck SM, Atkinson MJ, **Mastroberardino PG**, Tapio S.  
*Neonatal Irradiation Leads to Persistent Proteome Alterations Involved in Synaptic Plasticity in the Mouse Hippocampus and Cortex.*  
**J Proteome Res.** 2015 Nov 6;14(11):4674-86.
- 37 Birket MJ, Ribeiro MC, Kosmidis G, Ward D, Leitoguinho AR, van de Pol V, Dambrot C, Devalla HD, **Mastroberardino PG**, Atsma D, Passier R, Mummery CL  
*Contractile defect caused by mutation in MYBPC3 revealed under conditions optimized for human PSC-cardiomyocyte function*  
**Cell Reports** 2015 Oct 27;13(4):733-45.
- 36 Aizenman E and **Mastroberardino PG.**  
*Metals in Neurodegeneration*  
**Neurobiol Dis.** 2015 Sep;81:1-3. doi: 10.1016/j.nbd.2015.08.012.
- 35 Cervellati C, Sticozzi C, Romani A, Belmonte G, De Rasmio D, Signorile A, Cervellati F, Milanese C, **Mastroberardino PG**, Pecorelli A, Savelli V, Forman HJ, Hayek J, Valacchi G.  
*Impaired enzymatic defensive activity, mitochondrial dysfunction and proteasome activation are involved in RTT cell oxidative damage.*  
**Biochim Biophys Acta** 2015 Jul 17. pii: S0925-4439(15)00206-9. doi: 10.1016/j.bbadis.2015.07.014.
- 34 van den Beukel JC, Grefhorst A, Hoogdijn MJ, Steenbergen J, **Mastroberardino PG**, Dor FJ, Themmen AP.  
*Women have more potential to induce browning of perirenal adipose tissue than men.*  
**Obesity (Silver Spring)** 2015 Aug;23(8):1671-9. doi: 10.1002/oby.21166.
- 33 Kempf SJ, Moertl S, Sepe S, von Toerne C, Hauck SM, Atkinson MJ, **Mastroberardino PG**, Tapio S.  
*Low-dose ionizing radiation rapidly affects mitochondrial and synaptic signaling pathways in murine hippocampus and cortex.*  
**J Proteome Res.** 2015 May 1;14(5):2055-64. doi: 10.1021/acs.jproteome.5b00114.
- 32 Altuntas S, D'Eletto M, Rossin F, Hidalgo LD, Farrace MG, Falasca L, Piredda L, Cocco S, **Mastroberardino PG**, Piacentini M, Campanella M. *Type 2 Transglutaminase, mitochondria and Huntington's disease: menage a trois.*  
**Mitochondrion** 2014 Nov;19 Pt A:97-104. doi: 10.1016/j.mito.2014.09.008.
- 31 van den Beukel JC, Grefhorst A, Quarta C, Steenbergen J, **Mastroberardino PG**, Lombès M, Delhanty PJ, Mazza R, Pagotto U, van der Lely AJ, Themmen APN  
*Direct activating effects of adrenocorticotrophin hormone (ACTH) on brown adipose tissue are attenuated by corticosterone*  
**FASEB J.** 2014 Aug 1. pii: fj.14-254839.
- 30 Rossin F, D'Eletto M, Falasca L, Sepe S, Cocco S, Fimia GM, Campanella M, **Mastroberardino PG**, Farrace MG, Piacentini M  
*Transglutaminase 2 ablation leads to mitophagy impairment associated with a metabolic shift towards aerobic glycolysis*  
**Cell Death Differ.** 2015 Mar;22(3):408-18. doi: 10.1038/cdd.2014.106.
- 29 Sanders LH, McCoy J, Hu X, **Mastroberardino PG**, Dickinson BC, Chang CJ, Chu CT, Van Houten B, Timothy Greenamyre J  
*Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease*  
**Neurobiol Dis.** 2014 Jun 27. doi: 10.1016/j.nbd.2014.06.014.
- 28 Ambrosi G, Ghezzi C, Sepe S, Milanese C, Payan-Gomez C, Bombardieri CR, Armentero MT, Zangaglia R, Pacchetti C, **Mastroberardino PG**, Blandini F  
*Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease*  
**BBA - Molecular Basis of Disease** 2014 May 20;1842(9):1385-1394. doi: 10.1016/j.bbadis.2014.05.008.  
**Co-corresponding author and equal contribution with FB**

- 27 Birket MJ, Casini S, Kosmidis G, Elliott DA, Gerencser AA, Baartscheer A, Schumacher C, **Mastroberardino PG**, Elefanty AG, Stanley EG, Mummery CL  
*PGC-1 $\alpha$  and Reactive Oxygen Species Regulate Human Embryonic Stem Cell-Derived Cardiomyocyte Function*  
**Stem Cell Reports** 2013 Dec 12;1(6):560-74.
- 26 van der Burgh R, Nijhuis L, Pervolaraki K, Compeer EB, Jongeneel LH, van Gijn M, Coffier PJ, Murphy MP, **Mastroberardino PG**, Frenkel J, Boes M  
*Defects in mitochondrial clearance predispose human monocytes to interleukin-1 $\beta$  hypersecretion*  
**J Biol Chem.** 2013 Dec 19. doi: 10.1074/jbc.M113.536920.
- 25 Uittenboogaard LM, Payan-Gomez C, Pothof J, van Ijcken W, **Mastroberardino PG**, van der Pluijm I, Hoeijmakers JH, Tresini M  
*BACH2: A marker of DNA damage and ageing*  
**DNA Repair (Amst)** 2013 Sep 24.
- 24 Sepe S, Nardacci R, Fanelli F, Rosso P, Bernardi C, Cecconi F, **Mastroberardino PG**, Piacentini M, Moreno S  
*Expression of Beclin 1 regulated-autophagy in mouse brain during physiological and Alzheimer type aging.*  
**Neurobiology of Aging** 2013 Aug 1.
- 23 Sepe S, Payan-Gomez C, Milanese C, Hoeijmakers JH, and **Mastroberardino PG** (2013)  
*Nucleotide excision repair in chronic neurodegenerative diseases*  
**DNA Repair (Amst)** 2013 Aug;12(8):568-77.
- 22 Filomeni G, Bolaños JP, **Mastroberardino PG**  
*Redox Status and Bioenergetics Liaison in Cancer and Neurodegeneration*  
**Int J Cell Biol** 2012; 2012:659645.
- 21 Di Maio R, **Mastroberardino PG**, Hu X, Montero LM, Greenamyre JT.  
*Thiol oxidation and altered NR2B/NMDA receptor functions in in vitro and in vivo pilocarpine models: Implications for epileptogenesis.*  
**Neurobiol Dis.** 2012 Jul 21;49C:87-98.
- 20 Di Maio R, **Mastroberardino PG**, Hu X, Montero L, Greenamyre JT.  
*Pilocarpine alters NMDA receptor expression and function in hippocampal neurons: NADPH oxidase and ERK1/2 mechanisms.*  
**Neurobiol Dis.** 2011 Jun;42(3):482-95. doi: 10.1016/j.nbd.2011.02.012.  
**Equal contribution** with RDM.
- 19 Horowitz M, Milanese C, Di Maio R, Hu X, Montero LM, Sanders LH, Tapias V, Sepe S, van Cappellen WA, Burton EA, Greenamyre T, and **Mastroberardino PG**.  
*Single-cell redox imaging demonstrates a distinctive response of dopaminergic neurons to oxidative insults.*  
**Antioxid Redox Signal.** 2011 Aug 15;15(4):855-71. doi: 10.1089/ars.2010.3629
- 18 Shah SR, Esni F, Jakub A, Paredes J, Lath N, Malek M, Potoka DA, Prasad K, **Mastroberardino PG**, Shiota C, Guo P, Miller KA, Hackam DJ, Burns RC, Tulachan SS, Gittes GK  
*Embryonic mouse blood flow and oxygen correlate with early pancreatic differentiation.*  
**Dev Biol.** 2011 Jan 15;349(2):342-9.
- 17 **Mastroberardino PG** and Piacentini M  
*Type 2 Transglutaminase in Huntington's Disease: a double-edged sword with clinical potential.*  
**J Intern Med.** 2010 Nov;268(5):419-3.
- 16 Greenamyre JT, Cannon JR, Drolet R, **Mastroberardino PG**  
*Lessons from the rotenone model of Parkinson's disease.*  
**Trends Pharmacol Sci.** 2010 Apr;31(4):141-2.

- 15 Bayir H, Kapralov AA, Jiang J, Huang Z, Tyurina YY, Tyurin VA, Zhao Q, Belikova NA, Vlasova II, Maeda A, Zhu J, Na HM, **Mastroberardino PG**, Sparvero LJ, Amoscato AA, Chu CT, Greenamyre JT, Kagan VE  
*Peroxidase mechanism of lipid dependent cross-linking of synuclein with cytochrome c: protection against apoptosis versus delayed oxidative stress in Parkinson's disease.*  
**J Biol Chem.** 2009 Jun 5;284(23):15951-69.
- 14 **Mastroberardino PG**, Hoffman EK, Horowitz MP, Betarbet R, Taylor G, Cheng D, Na HM, Gutekunst CA, Gearing M, Chu CT, Peng J, Greenamyre JT  
A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease.  
**Neurobiol Dis.** 2009 Jun 34(3):417-31. doi: 10.1016/j.nbd.2009.02.009.  
**Corresponding author.**
- 13 Rodolfo C, Falasca L, Di Giacomo G, **Mastroberardino PG**, Piacentini M.  
More than two sides of a coin? How to detect the multiple activities of type 2 transglutaminase.  
**Methods Enzymol.** 2008 442:201-12.
- 12 **Mastroberardino PG**, Orr AL, Hu X, Na HM, Greenamyre JT.  
*A FRET based method to study protein thiol oxidation in histological preparations.*  
**Free Rad Biol & Med.** 2008 Oct 1;45(7):971-81. doi: 10.1016/j.freeradbiomed.2008.06.018.  
**Corresponding author.**
- 11 Orr AL, Li S, Wang C, Li E, Wang J, Rong J, Xu X, **Mastroberardino PG**, Greenamyre JT, Li X  
*N-terminal Mutant Huntingtin Associates with Mitochondria and Impairs Mitochondrial Trafficking.*  
**J Neurosci.** 2008 Mar 12;28(11):2783-92. doi: 10.1523/JNEUROSCI.0106-08.2008.
- 10 Battaglia G, Farrace MG, **Mastroberardino PG**, Viti I, Fimia GM, Van Beeumen J, Devreese B, Melino G, Molinaro G, Busceti CL, Biagioni F, Nicoletti F and Piacentini M.  
*Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental model of extrapyramidal disorders.*  
**J.Neurochem.** 2007 Jan; 100(1):36-49
- 9 **Mastroberardino PG**, Farrace MG, Viti I, Pavone F, Fimia GM, Melino G, Rodolfo C and Piacentini M  
*"Tissue"transglutaminase regulates mitochondrial respiratory complexes in vivo through its protein disulphide isomerase activity.*  
**Biochim Biophys Acta** 2006 Sep-Oct;1757(9-10):1357-65. doi:10.1016/j.bbabbio.2006.07.007
- 8 Szondy Z, **Mastroberardino PG**, Váradi J, Farrace MG, Nagy N, Bak I, Viti I, Wieckowski MR, Melino G, Rizzuto G, Tószaki A, Fésüs L and Piacentini M  
*Tissue transglutaminase (TG2) protects cardiomyocytes against ischemia/reperfusion injury by regulating ATP synthesis*  
**Cell Death Differ.** 2006 Oct;13(10):1827-9. doi:10.1038/sj.cdd.4401889  
**Equal contribution with SZ.**
- 7 Betarbet R, Canet-Aviles RM, Sherer TB, **Mastroberardino PG**, McLendon C, Kim JH, Lund S, Na HM, Taylor G, Bence NF, Kopito R, Seo BB, Yagi T, Yagi A, Klinefelter G, Cookson MR, Greenamyre JT.  
*Intersecting pathways to neurodegeneration in Parkinson's disease: Effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system.*  
**Neurobiol Dis.** 2006 May;22(2):404-20.
- 6 Piacentini M, Amendola A, Ciccocanti F, Falasca L, Farrace MG, **Mastroberardino PG**, Nardacci R, Oliverio S, Piredda L, Rodolfo C, Autuori F.  
*Type 2 transglutaminase and cell death.*  
**Prog Exp Tumor Res.** 2005 38:58-74.
- 5 Vahsen N, Cande C, Briere JJ, Benit P, Joza N, Larochette N, **Mastroberardino PG**, Pequignot MO, Casares N, Lazar V, Feraud O, Debili N, Wissing S, Engelhardt S, Madeo F, Piacentini M, Penninger JM, Schagger H, Rustin P, Kroemer G.  
*AIF deficiency compromises oxidative phosphorylation.*  
**EMBO J.** 2004 23(23):4679-89. doi: 10.1038/sj.emboj.7600461

- 4 Szondy Z., Sarang Z., Piacentini M., **Mastroberardino P.G.**, Falasca L., Aeschlimann D., Mólnar P., Németh T., Sze E., Lakos G., Birckbichler P., Melino G. and Fesus L.  
*Tissue transglutaminase is required for proper phagocytosis and to prevent inflammation and autoimmunity.*  
**Proc Natl Acad Sci U S A.** 2003 Jun 24;100(13):7812-7.
- 3 Piacentini M, Evangelisti C, **Mastroberardino PG**, Nardacci R, Kroemer G.  
*Does prothymosin-alpha act as molecular switch between apoptosis and autophagy?*  
**Cell Death Differ.** 2003 Sep;10(9):937-9.
- 2 Turella P, Pedersen JZ, Caccuri AM, De Maria F, **Mastroberardino P**, Lo Bello M, Federici G, Ricci G.  
*Glutathione transferase superfamily behaves like storage proteins for dinitrosyl-diglutathionyl-iron complex in heterogeneous systems.*  
**J Biol Chem.** 2003 Oct 24;278(43):42294-9.
- 1 **Mastroberardino PG**, Iannicola C., Nardacci R., Bernassola F., De Laurenzi V., Melino G., Moreno S., Pavone F., Oliverio S., Fesus L and Piacentini M.  
*Tissue transglutaminase ablation reduces neuronal death in a mouse model of Huntington's disease.*  
**Cell Death Differ.** 2002 Sep;9(9):873-80. doi:10.1038/sj.cdd.4401093